
-
Sorrento Therapeutics OTC Markets OTCPK:SRNE Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Location: 4955 Directors Place, San Diego, CA, 92121, United States | Website: https://www.sorrentotherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
135M
Cash
80.64M
Avg Qtr Burn
-58.66M
Short % of Float
11.98%
Insider Ownership
0.00%
Institutional Own.
0.01%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SP-102 (SEMDEXA™) Details Sciatica , Spine disorder | NDA FDA meeting | |
STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor) Details Lung disease, Lung cancer, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
OVYDSO (STI-1558) Details COVID-19 | Phase 3 Initiation | |
SP-103 Details Chronic lower back pain | Phase 2 Data readout | |
Phase 2 Data readout | ||
COVI-DROPS Details COVID-19 | Phase 2 Data readout | |
STI-1499 (COVIGUARD™) Details COVID-19 | Phase 1 Data readout | |
STI-3031 (anti-Pd-L1 antibody) Details Urothelial cancer, Cancer | Failed Discontinued | |
STI-2020 (COVI-AMG) Details COVID-19, Solid tumor/s | Failed Discontinued | |
Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Failed Discontinued | |
Failed Discontinued | ||
Failed Discontinued |